The patent for dasatinib, identified by U.S. Patent No. 6,596,746 B1, is a key piece of intellectual property for the drug. This patent was filed by Bristol-Myers Squibb and covers aspects of the composition of matter for dasatinib [1].
When does the dasatinib patent expire?
The expiration date for U.S. Patent No. 6,596,746 B1, regarding dasatinib, is a critical factor for market entry of generic versions. Patent expiration timelines can be complex due to potential extensions and legal challenges. Information on specific patent expiration dates for drugs like dasatinib is often tracked by specialized services [2].
What does the dasatinib patent protect?
U.S. Patent No. 6,596,746 B1 specifically protects the composition of matter for dasatinib [1]. This means it covers the chemical structure of the active pharmaceutical ingredient itself, providing a foundational layer of exclusivity. Other patents may exist that cover methods of use, manufacturing processes, or specific formulations of dasatinib.
Who is challenging the dasatinib patent?
Challenges to drug patents, often initiated by generic manufacturers seeking to enter the market, are common. These challenges can involve litigation to invalidate the patent or argue that a proposed generic product does not infringe. Information regarding specific legal challenges to U.S. Patent No. 6,596,746 B1 would typically be found in patent litigation databases or through pharmaceutical industry news [2].
How does dasatinib work and what is it used for?
Dasatinib is a tyrosine kinase inhibitor used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [3]. It works by blocking the activity of specific enzymes (tyrosine kinases) that promote the growth of cancer cells [3].
What are the alternatives to dasatinib?
For patients with CML and Ph+ ALL, other tyrosine kinase inhibitors (TKIs) are available as treatment options. These include imatinib, nilotinib, and bosutinib, among others. The choice of treatment depends on various factors, including disease stage, patient characteristics, and prior treatment history [4].
How are drug patents like dasatinib's enforced?
Enforcement of drug patents, including U.S. Patent No. 6,596,746 B1, primarily occurs through patent litigation. If a company believes a competitor is infringing on their patent, they can file a lawsuit seeking an injunction to stop the infringing activity and potentially damages. Generic drug manufacturers often file "Paragraph IV" certifications, challenging existing patents as part of their abbreviated new drug application (ANDA) process, which can trigger patent litigation [5].
What are the implications of patent expiration for dasatinib?
The expiration of U.S. Patent No. 6,596,746 B1 and any other relevant patents for dasatinib would open the door for generic manufacturers to produce and market their versions of the drug. This typically leads to a significant decrease in the price of the medication, increasing patient access [6].
Sources:
[1] https://patents.google.com/patent/US6596746B1/en
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.gov/drug-dictionary/def/dasatinib
[4] https://www.lls.org/leukemia/chronic-myeloid-leukemia/treatment
[5] https://www.fda.gov/drugs/patent-certification-and-exclusivity-information-drugs/paragraph-iv-patent-igations
[6] https://www.brookings.edu/research/the-impact-of-patent-expiration-on-drug-prices-and-access/